A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma

The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA). Randomized controlled trials (RCTs) related to chemotherapy regimens based on cisplatin and fluorouracil for EGJA were included from the PubMed, EMBASE and Cochrane Library electronic databases (from inception to June 2016). Direct and indirect evidence were combined to calculate the pooled odds ratio (OR) and its 95% confidence interval (95% CI) as well as to draw the surface under the cumulative ranking (SUCRA) curves. This NMA finally enrolled ten eligible RCTs with the following five regimens: cisplatin plus fluorouracil (cisplatin+fluorouracil), cisplatin+fluorouracil-based chemotherapy (cisplatin+fluorouracil+docetaxel/epirubicin/irinotecan), fluorouracil-based chemotherapy (fluorouracil+docetaxel/doxorubicin/methotrexate/irinotecan), cisplatin-based chemotherapy (cisplatin+docetaxel/epirubicin/irinotecan/capecitabine/s-1) and other drug-based chemotherapy (docetaxel/irinotecan/capecitabine). These results revealed that compared with a cisplatin+ fluorouracil-based chemotherapy regimen, the fluorouracil-based chemotherapy regimen had a lower overall response rate (ORR) and partial response (PR) for EGJA patients (ORR: OR=0.43, 95% CI=0.22–0.86; PR: OR=0.46, 95% CI=0.23–0.91). Cluster analyses suggested that the cisplatin+fluorouracil-based chemotherapy regimen had the best short-term efficacy for EGJA in terms of the complete response (CR), PR, ORR, stable disease (SD) and progression disease (PD). Our results indicated that cisplatin+fluorouracil-based chemotherapy regimens may have the best short-term efficacy in the treatment of EGJA.

Study on the application of laparoscopy-assisted radical gastrectomy for gastric cancer in the elderly / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To evaluate the feasibility and efficacy of laparoscopy-assisted D2 radical gastrectomy for elderly patients with gastric cancer.</p><p><b>METHODS</b>From October 2007 to October 2012, 233 gastric cancer patients over 65 years underwent D2 lymph node dissection. Among them, 109 patients underwent laparoscopy-assisted radical gastrectomy(LAG group), while 124 patients underwent conventional open gastrectomy(OG group).</p><p><b>RESULTS</b>Compared to the OG group, LAG group was associated with less bleeding [(102.5±34.3) ml vs. (181.7±73.8) ml, P<0.05], quicker postoperative recovery of bowel function[(2.8±0.6) d vs. (4.0±1.2) d, P<0.05], shorter postoperative length of hospital stay[(10.7±7.5) d vs.(14.2±6.5) d, P<0.05], longer operative time [(231.2±51.4) min vs. (208.5±53.6) min, P<0.05]. The postoperative complication rate of LAG group and OG group was 10.1%(11/109) and 21.0%(26/124) respectively(P<0.05). Short-term quality of life of LAG group was better than that of OG group(P<0.05). The 5-year survival rates were 54.5% and 59.2% in LAG and OG groups respectively, and there was no significant difference(P>0.05).</p><p><b>CONCLUSIONS</b>Efficacy of laparoscopy-assisted D2 radical gastrectomy is similar to open gastrectomy in elderly gastric cancer patients with less invasiveness.</p>